Elite Pharmaceuticals Inc (ELTP)

[no2koolaid]

It is beyond hilarious to argue Elite's revenues that are clear and irrefutably growing; as noted with increasing sales of generics.

It is always something to argue that is not perfect. Yet, astute investors recognize there is simply no company that is perfect. Gilead gets criticized for the perception it will be unable to extend its HIV franchise; Apple gets questioned as to whether it has cheap labor from China to aid in cost containment and, thereby, artificially inflating profits; Coke gets criticized for a shrinking desire by consumers to purchase carbonated brown sugar water; even the inimitable Pfizer for financial engineering rather than product development and growth. So, should we be surprised that a small company like Elite, that is seeking to break into a major growth market, has a few issues? But, let's be clear, revenues do not seem to be one of them...